The utilization of artificial intelligence (“AI”) is becoming ubiquitous across a wide range of industry sectors. The biotech industry is no exception.
AI-driven platforms have become increasingly useful to biotech...more
10/18/2024
/ Artificial Intelligence ,
Biotechnology ,
Disclosure Requirements ,
Duty to Disclose ,
Inventions ,
Inventors ,
Machine Learning ,
Patent Act ,
Patent Applications ,
Pharmaceutical Industry ,
Prescription Drugs ,
USPTO
As I have written about previously, the IP and competitive landscape for mRNA and lipid nanoparticles is complex. Pioneers, mid-stage, and new market entrants must take careful consideration of this landscape and develop a...more
Partner Dan Shores will present a webinar titled "The mRNA/Lipid Nanoparticle Competitive and Litigation Landscape" for Medmarc, the leading expert in the products liability risks facing medical technology and life sciences...more
8/22/2023
/ Competition ,
Coronavirus/COVID-19 ,
Health Care Providers ,
Health Technology ,
Intellectual Property Protection ,
Life Sciences ,
Medical Technology Companies ,
Moderna Inc. ,
Patent Litigation ,
Pfizer ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Regulatory Approval ,
Webinars
Substantial patent litigation activity occurred in the mRNA space in 2022, involving nearly all of the major mRNA and lipid nanoparticle (LNP) pioneers. Since this is the most significant happening in this space with respect...more
Several patent litigations have been filed involving mRNA pioneers such as Moderna, Inc. and BioNTech, Inc. (with Pfizer) over the past year relating to sales of the Moderna and BioNTech/Pfizer COVID-19 vaccine products...more
On August 16, 2022, Merck (NYSE: MRK) and Orna Therapeutics each announced that they entered into a collaboration agreement relating to the discovery, development and commercialization of therapeutics and vaccines in the...more
In the first major patent infringement lawsuit in the mRNA space, on February 28, 2022, Arbutus Biopharma Corporation (“Arbutus”) and Genevant Sciences GmbH (“Genevant”) sued Moderna, Inc. and ModernaTX, Inc. (collectively...more
On January 4, 2022, Judge Andrews from the United States District Court for the District of Delaware denied Sarepta Therapeutics, Inc.’s (“Sarepta”) Rule 12(b)(6) motion to dismiss a complaint for infringement of U.S. Patent...more
In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. In this post we provide a 2021 year in review update on mRNA pioneers and key players and offer additional...more
Universities and certain colleges in the United States (US) spend billions of dollars on research and development (R&D) each year to advance knowledge across the gamut of Arts, Humanities, and Science, Technology,...more
Google’s parent company Alphabet announced the launch of a new company this week dedicated to applying deep learning methods to drug discovery.
The new company is called Isomorphic Laboratories and will be led by Demis...more
mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria. Its efforts are geographically focused on Africa, and the company said it is furthering those efforts to...more
In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of the COVID-19 pandemic, we focused on market players BioNTech, Moderna and CureVac; in Part II, we discussed Translate...more
In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac. In this second post, we will focus on Translate BIO, Arcturus Therapeutics, and eTheRNA and discuss...more
Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the United States Food & Drug Administration (FDA) granted emergency regulatory approval for...more
Founders of an emerging company must decide early on in its growth cycle whether to require employees to assign their inventions (including rights to patent and patent applications –collectively “patent rights”) to the...more
3/29/2021
/ Artificial Intelligence ,
Assignments ,
Confidential Information ,
Fiduciary Duty ,
Intellectual Property Protection ,
Inventors ,
Joint Inventors ,
Patent Applications ,
Patents ,
Trade Secrets ,
USPTO
Hyundai is reportedly in the process of purchasing a large controlling interest in robot innovator Boston Dynamics from SoftBank in a deal valued at $1.1 billion.
The transaction, under which Hyundai will reportedly obtain...more
Founders of technology-based companies often recognize very early on that their company’s IP and related technology comprise a significant or even central part of the company’s overall value. Determining how to best protect...more
Moderna, one of the global leaders in developing a safe and effective vaccine to combat COVID-19, appears poised to get through clinical trials with a vaccine that is based on mRNA technology. As was recently announced,...more
11/16/2020
/ Coronavirus/COVID-19 ,
Final Written Decisions ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Moderna Inc. ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Popular ,
USPTO ,
Vaccinations
Last month, Moderna Therapeutics, one of the global leaders in the race to produce a COVID-19 vaccine, made the following statement regarding enforcement of its patents:
We feel a special obligation under the current...more
11/10/2020
/ Bayh-Dole Act ,
Biotechnology ,
Coronavirus/COVID-19 ,
Department of Defense (DOD) ,
European Commission ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Moderna Inc. ,
Patent Invalidity ,
Patent Ownership ,
Patents ,
Pharmaceutical Patents ,
Popular ,
Research and Development ,
USPTO ,
Vaccinations